Lexicon Pharmaceuticals/$LXRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Ticker
$LXRX
Sector
Primary listing
Employees
103
Headquarters
Website
LXRX Metrics
BasicAdvanced
$407M
-
-$0.33
1.18
-
Price and volume
Market cap
$407M
Beta
1.18
52-week high
$2.02
52-week low
$0.28
Average daily volume
2.1M
Financial strength
Current ratio
4.165
Quick ratio
4.053
Long term debt to equity
46.745
Total debt to equity
43.346
Interest coverage (TTM)
-8.44%
Profitability
EBITDA (TTM)
-105.47
Gross margin (TTM)
-43.39%
Net profit margin (TTM)
-206.43%
Operating margin (TTM)
-181.53%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
-22.14%
Return on equity (TTM)
-65.30%
Valuation
Price to revenue (TTM)
6.945
Price to book
3.14
Price to tangible book (TTM)
4.79
Price to free cash flow (TTM)
-3.952
Free cash flow yield (TTM)
-25.30%
Free cash flow per share (TTM)
-0.283
Growth
Revenue change (TTM)
1,504.83%
Earnings per share change (TTM)
-57.12%
3-year revenue growth (CAGR)
712.35%
10-year revenue growth (CAGR)
9.27%
3-year earnings per share growth (CAGR)
-20.09%
10-year earnings per share growth (CAGR)
-11.18%
What the Analysts think about LXRX
Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.
Bulls say / Bears say
Lexicon signed an exclusive licensing deal with Novo Nordisk for the obesity candidate LX9851, potentially valued up to $1 billion, with an upfront payment of $45 million. The agreement validates Lexicon’s pipeline and enhances its balance sheet (Reuters)
Topline results from the Phase 2b PROGRESS study for pilavapadin (LX9211) showed that the 10 mg dose achieved meaningful, consistent reductions in average daily pain, supporting progression to Phase 3 development (GlobeNewswire)
Lexicon posted net income of $3.3 million in Q2 2025, its first profitable quarter in recent years, after strategic cost cuts and strong licensing revenue, signaling better financial discipline and an improved cash runway (Lexicon Pharmaceuticals Q2 2025 Financial Results)
Phase 2b PROGRESS study of pilavapadin (LX9211) missed its primary endpoint with a p-value of 0.11, leading to an approximately 50% drop in LXRX shares and raising red flags over regulatory and commercial execution risks (Reuters)
Profitability in Q2 2025 was almost entirely due to a non-recurring licensing payment of $27.5 million, while core product sales from INPEFA® were just $1.3 million, highlighting major dependence on one-off revenues (Lexicon Pharmaceuticals Q2 2025 Financial Results )
The licensing deal for LX9851 includes only $75 million in upfront and near-term milestone payments; about $925 million is tied to future development and sales milestones, meaning most cash inflows are deferred and subject to execution risk (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
LXRX Financial Performance
Revenues and expenses
LXRX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals (LXRX) has a market cap of $407M as of September 16, 2025.
What is the P/E ratio for Lexicon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of September 16, 2025.
Does Lexicon Pharmaceuticals stock pay dividends?
No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Lexicon Pharmaceuticals dividend payment date?
Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.